Back to Search
Start Over
Asthma and allergic diseases are not risk factors for hospitalization in children with coronavirus disease 2019
- Source :
- Annals of Allergy, Asthma & Immunology
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Background Coronavirus disease 2019 (COVID-19) emerged as a pandemic toward the end of 2019, causing large numbers of people to become infected and die. Objective To determine whether allergic diseases are a risk factor for hospitalization in COVID-19. Methods We conducted a study including 107 pediatric patients after COVID-19 recovery. The International Study of Asthma and Allergies in Childhood Phase 3 questionnaires were distributed together with a detailed history of environmental factors and an allergic evaluation including skin prick tests, specific immunoglobulin E tests, and spirometry. We investigated the prevalence of allergic diseases and evaluated the factors associated with hospitalization in COVID-19. Results A total of 61 (57%) patients were hospitalized and 46 (43%) patients were followed closely in the outpatient clinic. The prevalences of allergic rhinitis, asthma, atopic dermatitis, and episodic wheezing were 10.3%, 6,5%, 4.7%, and 3.7%, respectively, within the whole study population. Although having asthma with or without allergic rhinitis, atopic dermatitis, and passive tobacco exposure were not found to be related to hospitalization because of COVID-19, having a pet at home was found to decrease the risk of hospitalization (odds ratio, 0.191; 95% confidence interval, 0.047-0.779; P = .02). Spirometry tests revealed a higher forced expiratory volume in one second to forced vital capacity ratio and a peak expiratory flow reversibility in hospitalized patients than in nonhospitalized ones (P = .02 and P = .003, respectively). Conclusion Asthma and allergic diseases do not seem to be risk factors for hospitalization in children because of COVID-19, and having a pet at home can be a protective effect. Pulmonary function testing seems to be important for monitoring lung damage after COVID-19.
- Subjects :
- Male
Allergy
Vital Capacity
DLCO, diffusing capacity for carbon monoxide
AR, Allergic rhinitis
Severity of Illness Index
Pulmonary function testing
0302 clinical medicine
Risk Factors
Sars-CoV
Forced Expiratory Volume
Surveys and Questionnaires
Immunology and Allergy
Outpatient clinic
Prospective Studies
infections
030212 general & internal medicine
Child
COVID
IL-13, interleukin-13
atopic dermatitis
medicine.diagnostic_test
Coinfection
Atopic dermatitis
CDC, The US Centers for Disease Control and Prevention
FEV1, forced expiratory volume in the first second
ICU, intensive care unit
CT, computed tomography
Hospitalization
Treatment Outcome
Child, Preschool
AD, Atopic dermatitis
PFT, pulmonary function testing
Female
Disease Susceptibility
Pulmonary and Respiratory Medicine
Spirometry
medicine.medical_specialty
Adolescent
pediatrics
ISAAC, International Study of Asthma and Allergies in Childhood
Immunology
sIgE, specific immunoglobulin E
FEF25–75, forced expiratory flow at 25%–75% of the vital capacity
Article
Dermatitis, Atopic
03 medical and health sciences
rhinitis
ACE-2, Angiotensin-converting enzyme-2
Internal medicine
medicine
Humans
Risk factor
Asthma
SARS-CoV-2
business.industry
COVID-19
Infant
Odds ratio
asthma
medicine.disease
Rhinitis, Allergic
030228 respiratory system
FVC, forced vital capacity
SPT, skin prick testing
PEF, peak expiratory flow
Tobacco Smoke Pollution
business
Subjects
Details
- ISSN :
- 10811206
- Volume :
- 126
- Database :
- OpenAIRE
- Journal :
- Annals of Allergy, Asthma & Immunology
- Accession number :
- edsair.doi.dedup.....443ab24b380af26b0defed77d15eeac2